Baclofen in Parkinson's disease.
In a controlled trial, baclofen (mean dose 45 mg daily) signficantly increased disability from Parkinsonism in 12 patients with the long-term levodopa syndrome. Peak dose choreoathetosis was not improved but benefit was observed in all four patients with "off period dystonia." Adverse side effects were common and severe, and included visual hallucinations, vomiting, and dizziness.
D000368:Aged; D000613:Aminobutyrates / Q000627:therapeutic use*; D001418:Baclofen / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*
D000613:Aminobutyrates; D007980:Levodopa; D001418:Baclofen